Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    VVUS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

VIVUS, Inc. : Trending News: VIVUS, SunTrust Banks, SAP AG, Google Inc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:15pm CEST

NEW YORK, April 19, 2013 - cheapstocks.us, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on VIVUS, SunTrust Banks, SAP AG, Google Inc.

VIVUS, Inc.(NASDAQ:VVUS) shares gained 3.97% to $12.57. The company on April 16 announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia® (phentermine and topiramate extended-release) capsules CIV. The amendment, submitted in October 2012, allows Qsymia to be dispensed through certified retail pharmacies, in addition to the existing network of certified mail-order pharmacies.

Is This A Turn Around New For VVUS? Get Free Report Here http://cheapstocks.us/index-lp2-aw.php?code=VVUS (OR Just copy and paste the link)

SunTrust Banks, Inc. (NYSE:STI) shares gained 1.72% to $27.71. The company on April 19, posted first quarter net income of $340 million from $245 million last year. Earnings per share grew 37 percent to $0.63 from $0.46 a year ago. Analysts expected the company to report earnings of $0.61 per share for the quarter. Total revenue, on a fully taxable-equivalent or FTE basis, dropped 5 percent to $2.114 billion. Revenue decreased 4 percent to $2.112 billion. Analysts had consensus revenue estimate of $2.25 billion for the quarter.

What Should Be The Fair Value Of STI After The Earnings? Find Out Here http://cheapstocks.us/index-lp2-aw.php?code=STI (OR Just copy and paste the link)

SAP AG (ADR)(NYSE:SAP) shares decreased 2.08% to $76.55. The company, on April 19, announced its financial results for the first quarter ended March 31, 2013. The company had a solid start to 2013 with 23% (25% at constant currencies) growth in non-IFRS software and cloud subscription revenue. SAP achieved ?824 million in non-IFRS software and cloud subscription revenue in the first quarter.

How Should investors Trade Sap After The Earnings? Get Free Trend Analysis Here http://cheapstocks.us/index-lp2-aw.php?code=SAP (OR Just copy and paste the link)

Looking forward, the company expects fiscal 2013 non-IFRS software and cloud subscription revenue to increase in a range of 14%-20% at constant currencies (fiscal 2012: EUR5.00 billion). The fiscal 2013 non-IFRS
cloud subscription and support revenue contributing to this growth is expected to be around EUR750 million at constant currencies (fiscal 2012: EUR343 million). The Company expects fiscal 2013 non-IFRS software and
software-related service revenue to increase in a range of 11%-13% at constant currencies (fiscal 2012: EUR13.25 billion).

Google Inc(NASDAQ:GOOG) shares increased 0.79% to $772. The company, on April 18, said core Internet business grew net revenue 23 percent in the first quarter, softening the effect of a sharp decline in its Motorola mobile phone division.

Get Complete Insight About GOOG?s Earnings Here http://cheapstocks.us/index-lp2-aw.php?code=GOOG (OR Just copy and paste the link)

The company reported a first-quarter profit of $3.35 billion, or $9.94 a share, compared with a profit of $2.89 billion, or $8.75 a share, for the year-earlier period. Adjusted revenue was $11.01 billion, compared with $8.14 billion in the same quarter the previous year. Adjusted profit was $11.58 a share. Analysts on average were expecting the company to report a profit of $10.65 a share, on revenue of $11.12 billion.

About cheapstocks.us
CheapStocks.us is a subscription-based investment newsletter that provides regular coverage, analysis, and commentary on Nasdaq, Pink Sheets and OTCBB Stocks. Subscribers receive intra-day stock analysis and commentary, as well as access to our regular Special Reports, and Trading Tools.

Disclaimer
Cheapstocks.us is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Cheapstocks.us is a wholly owned entity of a financial public relations firm. We have not been compensated by any of the companies listed in this news release.
Contacts:
cheapstocks.us
1419 Westwood Blvd Los
Angeles, CA
90024-4911
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VIVUS, INC.
10/09 VIVUS,INC. (NASDAQ : VVUS) Files An 8-K Notice of Delisting or Failure to Satisf..
10/06 VIVUS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
09/11 VIVUS : Alvogen adds qsymia to its anti obesity portfolio in korea
09/08 VIVUS, INC. : VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacr..
09/07 VIVUS,INC. (NASDAQ : VVUS) Files An 8-K Other Events
09/06 VIVUS : Announces Tacrolimus Receives Orphan Drug Designation in the European Un..
09/05 VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)
09/05 VIVUS : and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic o..
09/02 DR REDDY LABORATORIES : Stock sees huge buying in f&o segment
09/01 VIVUS : Dr. Reddy’s Lab settles patent litigation with Vivus Inc
More news
News from SeekingAlpha
10/05 YOUR DAILY PHARMA SCOOP : The First Trust NYSE Arca Biotechnology Index, Gilead'..
09/06 VIVUS' tacrolimus an Orphan Drug in Europe for pulmonary arterial hypertensio..
09/05 VIVUS establishes Qsymia distribution in Korea
08/30 Vivus settles Qsymia patent fight with Dr. Reddy's, generic version allowed J..
08/22 Vivid Potential Victory With Vivus, Inc. Convertible Bonds
Financials ($)
Sales 2017 71,0 M
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 1,16x
Capi. / Sales 2018 1,29x
Capitalization 82,3 M
Chart VIVUS, INC.
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | VVUS | US9285511005 | 4-Traders
Technical analysis trends VIVUS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 2,15 $
Spread / Average Target 176%
EPS Revisions
Managers
NameTitle
Seth H. Z. Fischer Chief Executive Officer & Director
David York Norton Chairman
Mark K. Oki Chief Financial & Accounting Officer
Santosh T. Varghese Chief Medical Officer
Jorge Plutzky Director
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.-32.36%82
BIOGEN31.85%72 855
CSL LIMITED38.38%50 210
ALEXION PHARMACEUTICALS14.62%31 299
GRIFOLS SA30.11%18 008
BIOMARIN PHARMACEUTICAL6.98%15 532